The National Institute for Health Research (NIHR), created in April 2006, is a “virtual” organisation often referred to as the research arm of the NHS. It funds health and care research in the UK, translating discoveries into practical products, treatments, devices and procedures, involving patients and the public in all its work. The NIHR also ensures that the NHS is able to support the research of other funders, thereby encouraging broader investment in, and economic growth from, health research.
Hampson, G., Lichten, C., Berdud, M., Pollitt, A., Mestre-Ferrandiz, J., Sussex, J., and Towse, A.
The Oxford Biomedical Research Centre (BRC) was established in April 2007. OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC since its inception.
The HTAi Asia Policy Forum meeting 2013 was held in Seoul, 13th -14th June 2013. This was the first of several annual meetings of the HTAi Asia Policy Forum. The topic of the meeting was: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
This report represents the background paper for the meeting, as developed by OHE. The report begins by looking at the increasing interest in the use of HTA, how HTA has evolved, where HTA has got to in Asia.
Barnsley, P., Hampson, G., Towse, A. and Henshall, C.
The second HTAi Asia Policy Forum meeting (2014) was held in Manilla, 10th -11th June 2014. The topic of the meeting was: Transferability of HTA. This report represents the background paper for the meeting, as developed by OHE.
The 2015 meeting of the HTAi Asia Policy Forum meeting was held in Singapore, 29th -30th October 2015. The topic of the meeting was: How can HTA meet the needs of health system and government decision makers? This report represents the background paper for the meeting, as developed by OHE.
The 2016 meeting of the HTAi Asia Policy Forum meeting was held in Kuala Lumpur, 17th -18th November 2016. The topic of the meeting was: Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies. This report represents the background paper for the meeting, as developed by OHE.
The paper begins with a discussion of how value can be defined, measured and factored into decisions on access and coverage.
Cubi-Molla, P., Shah, K.K., Garside, J., Herdman, M. and Devlin, N.
Several studies have found differences in health state values by age. We investigate whether and how age affects respondents’ Time Trade-Off (TTO) and Visual Analogue Scale (VAS) valuations of hypothetical EQ-5D health states using data from the 1993 MVH UK valuation study.
Mulhern, B., Feng, Y., Shah, K., van Hout, B., Janssen, B., Herdman, M. and Devlin, N.
Three EQ-5D value sets (the EQ-5D-3L, crosswalk and EQ-5D-5L) are now available for cost utility analysis in the UK and/or England. The value sets’ characteristics differ, and it is important to systematically assess the implications of these differences for the value generated. The aim of this paper is to compare the characteristics of the three value sets. In this Research Report we analyse and compare the predicted values from each of the three value sets, and also compare EQ-5D-3L and EQ-5D-5L data from patients who completed both measures.